Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.55 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341533 | 0.77 | MAPK14 (0.72) | PTGS1PTGS2MAPK14MLYCDBRD4 | |
| SCHEMBL4334913 | 0.77 | MAPK14 (0.59) | PTGS1PTGS2MAPK14MLYCDBRD4 | |
| SCHEMBL4334970 | 0.76 | MAPK14 (0.61) | PTGS1PTGS2MAPK14MLYCDBRD4 | |
| SCHEMBL3077231 | 0.74 | ADORA2A (0.48) | PTGS1PTGS2MAPK14GSK3BADORA2A | |
| SCHEMBL4332040 | 0.73 | MAPK14 (0.55) | PTGS1PTGS2MAPK14MLYCDBRD4 | |
| SCHEMBL4346446 | 0.73 | MAPK14 (0.62) | MAPK14MLYCDBRD4TDO2MAPK9 | |
| SCHEMBL2308019 | 0.73 | GSK3B (0.55) | PTGS1PTGS2MAPK14GSK3BADORA2A | |
| SCHEMBL4338473 | 0.72 | MAPK14 (0.57) | PTGS1PTGS2MAPK14MLYCDBRD4 | |
| SCHEMBL4336987 | 0.71 | MAPK14 (0.52) | PTGS1MAPK14MLYCDBRD4TDO2 | |
| SCHEMBL4334926 | 0.71 | MAPK14 (0.52) | PTGS1PTGS2MAPK14MLYCDBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | PTGS1 139/4885PTGS2 216/4885MAPK14 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.